IM Cannabis

IMCC

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$0.14

+0.00 (+1.05%)

Market Cap

$443,996

Exchange

NASDAQ Capital Market

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count falling — buybacks

−28.4% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 5.9M (2021) → 4.2M (2025)

IM Cannabis Corp. is a cannabis company that grows, processes, and sells medical marijuana products. It serves patients and medical customers in Israel and Germany, two of the more established legal medical cannabis markets in Europe and the Middle East. The company sources cannabis from licensed producers and distributes it under its own brands.

IM Cannabis makes money by selling medical cannabis flower, oils, and related products to pharmacies, clinics, and distributors. It operates primarily in Israel, where it has a stronger foothold, and has been expanding into Germany, which is one of the largest potential medical cannabis markets in Europe. The company is small, with a market cap near zero, and runs on thin margins with operating income barely breaking even. The main growth driver is Germany's expanding medical cannabis regulations, but the main risk is the company's limited financial resources and intense competition from larger, better-funded cannabis producers.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-49.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

69.1%ownership

Insiders own a meaningful stake in the company

Cash Runway

~4 years

$3M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

$3M cash & investments at current burn rate

Revenue declining

IM Cannabis's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

16.3%

Thin — 16.3% gross margin

Operating Margin

-19.3%

Losing money on operations — -19.3%

ROCE

-12.7%

Weak — -12.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-19.0%

Shrinking sales (-19.0% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-3.4%

Burning cash (-3.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/A

Data not available

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial